Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Why Bannerman, Clover, Polynovo, and Pro Medicus shares are pushing higher
5 ASX All Ords shares trading ex-dividend this week
Here are 3 ASX All Ords shares turning ex-dividend this week
Why Clover, Select Harvests, Whitehaven Coal, and Woodside shares are storming higher
3 ASX All Ordinaries shares defying today's rout to surge higher
Here are 5 ASX shares trading ex-dividend this week
Clover (ASX:CLV) share price sinks 7% on FY 2021 results
2 ASX dividend shares that could provide steady income retirement
Share Market News
ASX investors couldn't get enough of meme stocks last week
Consumer Staples & Discretionary Shares
Will 2021 go down as the year A2 and other milk share prices turned sour?
Top brokers name 3 ASX shares to buy today
Why AGL, Clover, QBE, & Volpara shares are pushing higher today
Yes, Clover Corporation has historically paid two fully franked shareholder dividends a year.
Clover Corporation generally pays its dividends in April and November.
No, Clover Corporation does not have a dividend reinvestment plan at the current time.
Clover Corporation listed on the ASX on 30 November 1999.
|30 Oct 2023||$0.0075||100.00%||Final||20 Nov 2023|
|05 Apr 2023||$0.0075||100.00%||Interim||27 Apr 2023|
|25 Oct 2022||$0.0100||100.00%||Final||22 Nov 2022|
|06 Apr 2022||$0.0050||100.00%||Interim||28 Apr 2022|
|25 Oct 2021||$0.0050||100.00%||Final||16 Nov 2021|
|07 Apr 2021||$0.0050||100.00%||Interim||29 Apr 2021|
|27 Oct 2020||$0.0250||100.00%||Final||18 Nov 2020|
|29 Oct 2019||$0.0175||100.00%||Final||20 Nov 2019|
|08 Apr 2019||$0.0063||100.00%||Interim||30 Apr 2019|
|29 Oct 2018||$0.0125||100.00%||Final||20 Nov 2018|
|09 Apr 2018||$0.0050||100.00%||Interim||01 May 2018|
|27 Oct 2017||$0.0000||100.00%||Final||20 Nov 2017|
|10 Apr 2017||$0.0025||100.00%||Interim||01 May 2017|
|27 Oct 2016||$0.0050||100.00%||Final||21 Nov 2016|
|11 Apr 2016||$0.0025||100.00%||Interim||02 May 2016|
|29 Nov 2010||$0.0125||100.00%||Final||15 Dec 2010|
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Clover Corporation Limited (ASX: CLV) provides nutritional ingredients, particularly omega-3 and omega-6 fatty acids. The company is involved in the production of encapsulated powders, and research and product development of infant nutrition and functional food ingredients.
Clover Corporation offers Nu-MegaHi tuna oils for use in infant formula and pharmaceutical products, as well as Ocean Gold refined tuna oils. Its products include DHA oils, DHA powders, and other nutritional oils drawn from patented microencapsulation technologies. Geographically, the group has a business presence in Australia, New Zealand, Asia, Europe, and the Americas. The majority of the company's revenue is derived from the Asian market.
|05 Dec 2023||$0.87||$0.00||0.00%||1,324||$0.88||$0.88||$0.87|
|04 Dec 2023||$0.87||$0.01||1.16%||25,488||$0.87||$0.87||$0.86|
|01 Dec 2023||$0.86||$0.03||3.61%||13,853||$0.85||$0.86||$0.84|
|30 Nov 2023||$0.83||$-0.03||-3.49%||34,133||$0.86||$0.86||$0.83|
|29 Nov 2023||$0.86||$0.00||0.00%||31,409||$0.86||$0.87||$0.82|
|28 Nov 2023||$0.86||$0.04||4.89%||34,719||$0.84||$0.86||$0.84|
|27 Nov 2023||$0.82||$0.01||1.24%||1,008,939||$0.83||$0.83||$0.81|
|24 Nov 2023||$0.81||$0.03||3.85%||69,211||$0.78||$0.83||$0.78|
|23 Nov 2023||$0.78||$-0.03||-3.68%||267,275||$0.78||$0.78||$0.70|
|22 Nov 2023||$0.82||$0.03||3.85%||53,628||$0.78||$0.82||$0.78|
|21 Nov 2023||$0.78||$0.00||0.00%||36,048||$0.81||$0.81||$0.78|
|20 Nov 2023||$0.78||$-0.05||-6.02%||171,975||$0.83||$0.83||$0.78|
|17 Nov 2023||$0.83||$0.00||0.00%||9,412||$0.83||$0.83||$0.81|
|16 Nov 2023||$0.83||$0.02||2.47%||4||$0.82||$0.83||$0.82|
|15 Nov 2023||$0.81||$-0.04||-4.71%||64,072||$0.83||$0.83||$0.81|
|14 Nov 2023||$0.85||$0.03||3.66%||647||$0.85||$0.85||$0.85|
|13 Nov 2023||$0.82||$-0.01||-1.21%||60,732||$0.83||$0.89||$0.82|
|10 Nov 2023||$0.83||$0.01||1.23%||81,919||$0.82||$0.85||$0.82|
|09 Nov 2023||$0.82||$-0.01||-1.22%||70,878||$0.81||$0.85||$0.81|
|08 Nov 2023||$0.82||$-0.02||-2.40%||43,971||$0.83||$0.83||$0.82|
|07 Nov 2023||$0.84||$-0.02||-2.34%||11,362||$0.83||$0.86||$0.82|
|23 Nov 2023||Peter Davey||Exercise||109,062||$85,068||
Conversion of securities. 645,486 Performance Rights
|23 Nov 2023||Peter Davey||Issued||249,712||$194,775||
Issue of securities. 7,54,548 Rights
|23 Nov 2023||Peter Davey||Issued||27,266||$21,267||
Conversion of securities.
|Mr Ian David Glasson||Non-Executive Director||Feb 2017||
Mr Glasson is former CEO of PGG Wrightson based in Christchurch, New Zealand. He was formerly CEO of Gold Coin Group / Zuellig Agriculture which managed a portfolio of animal feed operations and farming ventures throughout Southeast Asia. Prior to that he was CEO for seven years of Sucrogen (formerly the sugar business of listed entity CSR and now owned by Wilmar) which generated revenues of nearly $2bn and had contacts across the local and international food and beverage sector and retail market. He has also had agribusiness experience with Goodman Fielder and Gresham Rabo, as well as spending the first sixteen years of his career in the oil and gas sector with Esso.
|Ms Toni Brendish||Non-Executive Director||Oct 2020||
Ms Brendish was most recently Chief Executive of Westland Milk Products in the South Island of New Zealand. Westland produces a range of Dairy products including Infant Formula base powder and was New Zealand's Co-operative prior to being acquired by the Chinese Multinational; Yili. Prior to joining Westland Ms. Brendish worked for the Danone Group for 11 years running their Infant Formula and Dairy businesses including Manufacturing sites across Australia and New Zealand, Malaysia, and Indonesia. She has also worked for Kimberly-Clark, Colgate Palmolive and other Blue Chip FMCG organizations.
|Mr Rupert Anthony Harrington||Non-Executive DirectorNon-Executive Chairman||Jul 2015||
Mr Harrington is a company Director with over 30 years of experience as a Non-Executive Director of companies operating in manufacturing, industrial services, health, and technology. Mr Harrington's earlier career was in operational management in the UK and Australia.
|Mr Graeme Ambery Billings||Non-Executive Director||May 2013||
Mr Billings was a partner at Coopers and Lybrand and then PricewaterhouseCoopers (PwC) for 24 years. Mr Billings was head of PwC's Melbourne Assurance practice for several years as well as Global Leader of PwC's Industrial Products and Manufacturing industry group. Mr Billings brings a range of financial, corporate governance, internal control, commercial and corporate transactional skills to the Company.
|Mr Peter J Davey||Chief Executive OfficerManaging Director||Dec 2014||
Mr Davey has a record of building businesses across a diverse range of industry sectors. He has held senior management positions within several manufacturing and distribution companies operating in competitive and diverse markets. Mr Davey has strengths in sales and marketing, and development and implementation of strategies for growth. Mr Davey was formerly Executive Manager AgriProducts and a director of Viterra Australia Limited, responsible for the AgriProducts division that traded in agricultural inputs, fertilizer, seed, and wool. In earlier roles, Mr Davey headed the Sales and Marketing divisions of FMP Products and Hi Fert Pty Ltd. During his career, Mr Davey has had a particular focus on marketing-based businesses operating in the Asia and Oceania regions.
|Dr Simon Green||Non-Executive Director||Oct 2020||
Dr Green has 30 years of experience in the biotechnology industry focused on the discovery, development and commercialization of life saving medicines. He was actively involved in CSL's global expansion over a 17-year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Dr Green is currently the founder and CEO of Immunosis Pty Ltd, a start-up diagnostics Company. He is also a Venture Partner at BioScience Managers, a healthcare investment firm, and Non-Executive Director at Pharmaxis (chair of the Remuneration and nomination Committee's).
|Mr Andrew Allibon||Chief Financial OfficerCompany Secretary||May 2021||
|Andrew Allibon||Chief Financial OfficerCompany Secretary||
|Washington H Soul Pattinson & Company Limited||32,340,217||19.37%|
|Citicorp Nominees Pty Limited||23,343,528||13.98%|
|UBS Nominees Pty Ltd||14,907,428||8.93%|
|Hsbc Custody Nominees (Australia) Limited||12,967,326||7.76%|
|J P Morgan Nominees Australia Pty Limited||8,853,419||5.30%|
|Evelin Investments Pty Limited||7,550,000||4.52%|
|Anacacia Pty Ltd||6,393,701||3.83%|
|Incani & Papadopoulos Super Pty Ltd||2,010,000||1.20%|
|National Nominees Limited||1,995,837||1.20%|
|Mr Peter Howells||1,500,000||0.90%|
|Mr Garrie Ellice||1,000,000||0.60%|
|Mr Pei Yin Foo||900,000||0.54%|
|Baobab Nominees Pty Ltd||861,011||0.52%|
|Ms Nina Tschernykow||858,881||0.51%|
|Ganesh Super Fund||850,783||0.50%|
|Neweconomy Com Au Nominees Pty Limited||798,807||0.48%|
|Connaught Consultants (Finance) Pty Ltd||767,000||0.46%|
|Bellite Pty Ltd||719,600||0.43%|
|Columbus Investment Services Ltd||715,000||0.43%|
|Bnp Paribas Noms(Nz) Ltd||700,000||0.42%|